Ocuphire Pharma
summary of positive phase results for eye drops | Ocuphire Pharma
Company
Deck Type
Deck date
March 2021
Slide
19 of 29
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Results
March 2022
summary of positive phase results for eye drops | Ocuphire Pharma
Related slides by other companies
Valneva
IPO
April 2021
was well tolerated in phase safety profile within the expected range for an inactivated vaccine ans | Valneva
AngloAmerican
ESG
May 2022
attractive high margin growth options | AngloAmerican
DICE Therapeutics
Investor Presentation
March 2023
demonstrated a favorable safety and tolerability profile | DICE Therapeutics
NeuroSense Therapeutics
Investor Presentation
December 2023
strong clinical and commercial potential prime | NeuroSense Therapeutics
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights